Luciane Regina Cavalli, PhD
Professor, Research Institute Pelé Pequeno Príncipe
Faculdades Pequeno Príncipe, Curitiba, PR, Brazil
Adjunct Professor of Oncology
Lombardi Comprehensive Cancer Center
Georgetown University, Washington, DC, USA
Main research area​s
Breast Cancer
Cancer Cytogenetics
Cancer Genomics and Epigenomics
Cancer Disparities
​
​
Short Bio
I am a molecular cytogeneticist by training, with main research interest focused on the study of genomic instability in human tumors, particularly breast cancer, through the identification and characterization of the genetic alterations involved in these tumors' onset and progression. I am a Full Professor at Research Institute Pelé Pequeno Príncipe (IPPPP) (Curitiba, PR, Brazil) and at the Department of Oncology at Georgetown University Medical Center (GUMC) (Adjunct Line), a member of the Lombardi Comprehensive Cancer Center (LCCC), Breast Cancer Research Program, and at the University-Wide Initiative to Reduce Health Disparities. I maintain continuing and active educational and research collaborative programs with research institutes in USA, South Africa, France, and several universities in Brazil; the later, sponsored by Research Brazilian Foundations, such as CNPq (which I hold a Research Productivity Scholarship), CAPES, Fundação Araucária, FAPESP, and FAPEMA. In addition to my laboratory research and teaching activities, I also contribute to public service, acting as an editor and reviewer of scientific journals in the cancer research field and as member of the grant reviews panels of the National Institute of Health (NIH), Department of Defense/ USA Army (DOD), Cancer Research of United Kingdom, LCCC, European Science Foundation (ESF/FNR), and others.
Complete bio: http://lattes.cnpq.br/0523648966490396
Selected publications (https://pubmed.ncbi.nlm.nih.gov/?term=cavalli+lr&sort=date)
​
Sugita BM, Rodriguez Y, Fonseca AS, Nunes Souza E, Kallakury B, Cavalli IJ, Ribeiro EMSF, Aneja R, Cavalli LR. MiR-150-5p Overexpression in Triple-Negative Breast Cancer Contributes to the In Vitro Aggressiveness of This Breast Cancer Subtype. Cancers (Basel) 14:2156, 2022. PMID: 35565284
​
Lu C, Mahajan A, Hong SH, Galli S, Zhu S, Tilan JU, Abualsaud N, Adnani M, Chung S, Elmansy N, Rodgers J, Rodriguez O, Albanese C, Wang H, Regan M, Zgonc V, Blancato J, Krawczyk E, Gallicano GI, Girgis M, Cheema A, Iżycka-Świeszewska E, Cavalli LR, Pack SD, Kitlinska J. Hypoxia-activat ed neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma. Nat Commun. 13:2323, 2022. PMID: 35484119
​
Souza MF, Cólus IMS, Fonseca AS, Antunes VC, Kumar D, Cavalli LR. MiR-182-5p Modulates Prostate Cancer Aggressive Phenotypes by Targeting EMT Associated Pathways. Biomolecules 12:187, 2022. PMID: 35204688
​
Bhattarai S, Sugita BM, Bortoletto SM, Fonseca AS, Cavalli LR, Aneja R. QNBC Is Associated with High Genomic Instability Characterized by Copy Number Alterations and miRNA Deregulation. Int J Mol Sci 22:11548, 2021. PMID: 34768979
​
Turkistani S, Sugita BM, Fadda P, Marchi R, Afsari A, Naab T, Apprey V, Copeland RL Jr, Campbell MC, Cavalli LR, Kanaan Y. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer. BMC Cancer 21:861, 2021. PMID: 34315420
​
Ozawa PMM, Vieira E, Lemos DS, Souza ILM, Zanata SM, Pankievicz VC, Tuleski TR, Souza EM, Wowk PF, Urban CA, Kuroda F, Lima RS, Almeida RC, Gradia DF, Cavalli IJ, Cavalli LR, Malheiros D, Ribeiro EMSF. Identification of miRNAs Enriched in Extracellular Vesicles Derived from Serum Samples of Breast Cancer Patients. Biomolecules 10(1). pii: E150, 2020. PMID: 31963351
Fernandez AI, Geng X, Chaldekas K, Harris B, Duttargi A, Berry VL, Berry DL, Mahajan A, Cavalli LR, GyÅ‘rffy B, Tan M, Riggins RB. The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer. Breast Cancer Res Treat. 179:585-604, 2020. PMID:31741180
Sugita BM, Pereira SR, de Almeida RC, Gill M, Mahajan A, Duttargi A, Kirolikar S, Fadda P, de Lima RS, Urban CA, Makambi K, Madhavan S, Boca SM, Gusev Y, Cavalli IJ, Ribeiro EMSF, Cavalli LR. Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients. Oncotarget 10:6184-6203, 2019.
Gomig THB, Cavalli IJ, Souza RLR, Vieira E, Lucena ACR, Batista M, Machado KC, Marchini FK, Marchi FA, Lima RS, de Andrade Urban C, Cavalli LR, Ribeiro EMSF. Quantitative label-free mass spectrometry using contralateral and adjacent breast tissues reveal differentially expressed proteins and their predicted impacts on pathways and cellular functions in breast cancer. J Proteomics 199:1-14, 2019. PMID: 30772490
Mathias C, Bortoletto S, Centa A, Komechen H, Lima RS, Fonseca AS, Sebastião AP, Urban CA, Soares EWS, Prando C, Figueiredo BC, Cavalli IJ, Cavalli LR, Ribeiro EMFS. Frequency of the TP53 R337H variant in sporadic breast cancer and its impact on genomic instability. Sci Rep. 10:16614, 2020. PMID: 33024147
​
Ozawa PMM, Alkhilaiwi F, Cavalli IJ, Malheiros D, de Souza Fonseca Ribeiro EM,Cavalli LR . Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Biomolecules 172:713-723, 2018. PMID: 30173296
Lupicki K, Elifio-Esposito S, Fonseca AS, Weber SH, Sugita B, Langa BC, Pereira SRF, Govender D, Panieri E, Hiss DC, Abdul-Rasool S, Cavalli LR. Patterns of copy number alterations in primary breast tumors of South African patients and their impact on functional cellular pathways. Int J Oncol. 53:2745-2757, 2018. PMID: 3032039.
Mahajan A, Sugita BM, Duttargi AN, Fonseca AS, Kallakury B, Pohlmann P, Gusev Y, Cavalli LR. Genomic comparison of conditionally reprogrammed breast cancer cultures to their corresponding primary tumor. PlosOne 12:e0186190, 2017. PMID: 29049316.
Sheppard V, Cavalli LR. Dash C, Kanaan YM, Dilawari AA, Horton S, Makambi KJ. Correlates of Triple Negative Breast Cancer and Chemotherapy Patterns in Black and White Women with Breast Cancer. Clin Breast Cancer 17:232-238, 2017. PMID: 28189497
Stires H, Heckler MM, Fu X, Zhao L, Grasso CS, Quist M, Lewis J, Klimach U, Zwart A, Mahajan A, Györffy B, Cavalli LR, Riggins RB. Integrated Molecular Analysis of Tamoxifen-Resistant Invasive Lobular Breast Cancer Cells Identifies MAPK and GRM/mGluR Signaling as Therapeutic Vulnerabilities. Mol Cell Endocrinol. pii: S0303-7207(17)30509-9, 2017. PMID: 28935545.
​
Sugita B, Gill M, Mahajan A, Duttargi A, Kirolikar S, Almeida R, Regis K, Oluwasanmi OL, Marchi F, Marian C, Makambi K, Kallakury B, Sheahan L, Cavalli IJ, Ribeiro EM, Madhavan S, Boca S, Gusev Y, Cavalli LR. Differentially expressed miRNAs in triple negative breast cancer between African-American and non-Hispanic white women. Oncotarget 7:79274-79291, 2016. PMID: 27813494
​
Langa B, Oliveira M, Pereira S, Lupicki K, Marian C, Govender D, Panieri E, Hiss D, Cavalli I, Rasool S, Cavalli LR. Copy number analysis of the DLX4 and ERBB2 genes in South African breast cancer patients. Cytogenet Genome Res. 146:195-203, 2015. PMID: 26524685
Torresan C, Oliveira MMC, Pereira SRF, Ribeiro EMSF, Marian C, Gusev Y, Lima RS, Urban CA, Berg P, Haddad BR, Cavalli IJ, Cavalli LR. Increased copy number of the DLX4 homeobox gene in breast axillary lymph node metastasis. Cancer Genet. 207:177-87, 2014. PMID: 24947980
Ory V, Tassi E, Cavalli LR, Saenz F, Baker T, Mueller S, Furth P, Wellstein A, and Riegel AT. The nuclear coactivator amplified in breast cancer 1 maintains tumor initiating cells during development of Ductal Carcinoma In Situ. Oncogene. 33:3033-3042, 2014. PMID: 23851504